50 results on '"Russell, Stephen"'
Search Results
2. Oncolytic α-herpesvirus and myeloid-tropic cytomegalovirus cooperatively enhance systemic antitumor responses
3. Systemic Therapy of Disseminated Myeloma in Passively Immunized Mice Using Measles Virus-infected Cell Carriers
4. Improved Noninvasive In Vivo Tracking of AAV-9 Gene Therapy Using the Perchlorate-Resistant Sodium Iodide Symporter from Minke Whale
5. For the Success of Oncolytic Viruses: Single Cycle Cures or Repeat Treatments? (One Cycle Should Be Enough)
6. Improved Noninvasive In VivoTracking of AAV-9 Gene Therapy Using the Perchlorate-Resistant Sodium Iodide Symporter from Minke Whale
7. Oncolytic Virotherapy: A Contest between Apples and Oranges
8. Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model
9. 416. Enhanced Oncolytic Effect of Tumor Necrosis Factor Alpha Armed Engineered Oncolytic Measles Virus Therapy for Ovarian Carcinoma Cell Line
10. 185. Safety Study by Validated Immunoassays in a Phase III Study of Subjects with Inherited Retinal Dystrophy Due to Mutations in the Gene Encoding Human Retinal Pigment Epithelium-Specific Protein 65 (RPE65) Injected with Adeno-Associated Viral Vectors
11. 67. Rational Design of MicroRNA-Retargeted Coxsackievirus A21 Infectious RNA for Cancer Therapy
12. 411. Predicting Tumor Response to Oncolytic Virotherapy Using Dual Isotope SPECT/CT Imaging with NIS Reporter Gene and Duramycin
13. Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses
14. Cardiac AAV9 Gene Delivery Strategies in Adult Canines: Assessment by Long-term Serial SPECT Imaging of Sodium Iodide Symporter Expression
15. 551. Longitudinal High Resolution 3-D Imaging of AAV Gene Expression In Vivo
16. 429. Optimizing Intratumoral Oncolytic Virus Delivery Using Hemodynamic Manipulations
17. 75. MicroRNA-Based Multi-Tissue Detargeted Mengovirus Therapy for Multiple Myeloma
18. 70. Safety, Toxicity and Efficacy of Systemic Recombinant VSV Therapy in Pet Dogs With Spontaneous Cancer
19. 428. VSV Produced in CD55 Expressing Cells Has Better Resistance To Neutralization With Non-Immune Human Serum
20. 74. The Mechanism of Hepatotoxicity from IV Administration of High Dose VSV
21. Amalgamating Oncolytic Viruses to Enhance Their Safety, Consolidate Their Killing Mechanisms, and Accelerate Their Spread
22. Expression of Immunomodulatory Neutrophil-activating Protein of Helicobacter pylori Enhances the Antitumor Activity of Oncolytic Measles Virus
23. Myeloma Xenograft Destruction by a Nonviral Vector Delivering Oncolytic Infectious Nucleic Acid
24. Noninvasive Imaging and Radiovirotherapy of Prostate Cancer Using an Oncolytic Measles Virus Expressing the Sodium Iodide Symporter
25. Converting Tumor-specific Markers Into Reporters of Oncolytic Virus Infection
26. Intravascularly Administered RGD-Displaying Measles Viruses Bind to and Infect Neovessel Endothelial Cells In Vivo
27. MicroRNAs and the Regulation of Vector Tropism
28. Interleukin-13 Displaying Retargeted Oncolytic Measles Virus Strains Have Significant Activity Against Gliomas With Improved Specificity
29. History of Oncolytic Viruses: Genesis to Genetic Engineering
30. Epidermal Growth Factor Receptor (EGFR)–Retargeted Measles Virus Strains Effectively Target EGFR- or EGFRvIII Expressing Gliomas
31. Engineering Oncolytic Measles Virus to Circumvent the Intracellular Innate Immune Response
32. Infected Cell Carriers: A New Strategy for Systemic Delivery of Oncolytic Measles Viruses in Cancer Virotherapy
33. Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA–protease interactions
34. 58. Oncolytic Measles Virus Delivery by Infected Cell Carriers–A Strategy To “By-Pass” the Pre-Existing Humoral Immune Response
35. 430. EGFRvIII Retargeted Oncolytic Measles Virus Strains Have Significant Antitumor Activity Against Gliomas
36. 436. Coxsackievirus A21 Has Potent Oncolytic Activity in Multiple Myeloma
37. 432. Characterization of a Novel Oncolytic Measles Virus Retargeted Against the Urokinase Receptor: In Vitro and In Vivo Studies
38. 729. Phase I Trial of Intraperitoneal (IP) Administration of a Measles Virus (MV) Strain Expressing the Human Carcinoembryonic Antigen (CEA) in Ovarian Cancer Patients
39. 957. Effect of Ligand Binding Affinity and Receptor Density in Relation to Biology of Retargeted Viruses
40. 44. Combination of Oncolytic Measles Virus Strains and Radiation Therapy Has Synergistic Activity in the Treatment of Glioblastoma Multiforme
41. 482. T Cells as Carriers for Systemic Measles Virotherapy of Multiple Myeloma
42. A Preclinical Large Animal Model of Adenovirus-Mediated Expression of the Sodium–Iodide Symporter for Radioiodide Imaging and Therapy of Locally Recurrent Prostate Cancer
43. Systemic Therapy of Disseminated Myeloma in Passively Immunized Mice Using Measles Virus-infected Cell Carriers.
44. 719. Neutralization of Free but Not Cell Associated Oncolytic Measles Vurses by Antibody and Complement
45. 303. Validating CD46 as a Possible Mechanism Contributing to MV-Edm Oncolytic Specificity
46. 721. Measles Virus for Cancer Gene Therapy of Primary Liver Tumors
47. 720. EGFRvIII Retargeted Oncolytic Measles Virus Strains Have Significant Antitumor Activity Against Gliomas
48. 297. Radiovirotherapy in Ovarian Cancer Using Recombinant Measles Expressing Sodium Iodide Symporter
49. 73. Fully Retargeted Oncolytic Measles Viruses for Cancer Therapy
50. 47. Ex Vivo Hypothermic Recirculatory Adenoviral Gene Transfer to the Transplanted Pig Heart
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.